Cargando…

Comparative efficacy of indacaterol in chronic obstructive pulmonary disease

Long-acting bronchodilators have been shown to improve multiple clinical outcomes in chronic obstructive pulmonary disease (COPD) including lung function, symptoms, dyspnea, quality of life, and exacerbations. Indacaterol is a novel, inhaled, long-acting β2-agonist providing 24-hour bronchodilation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribeiro, Marcos, Chapman, Kenneth R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299544/ https://www.ncbi.nlm.nih.gov/pubmed/22419862 http://dx.doi.org/10.2147/COPD.S19805

Ejemplares similares

Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol
por: Feldman, Gregory J
Publicado: (2013)

Indacaterol for Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis
por: Chung, Vincent C. H., et al.
Publicado: (2013)

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease
por: Hataji, Osamu, et al.
Publicado: (2013)

Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea
por: Yum, Ho-Kee, et al.
Publicado: (2017)

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease
por: Nishijima, Yu, et al.
Publicado: (2015)

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
por: Lee, Sang Haak, et al.
Publicado: (2021)

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches
por: Renard, Didier, et al.
Publicado: (2011)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease
por: Burgel, Pierre-Régis, et al.
Publicado: (2017)

Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2011)

Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
por: Ulrik, Charlotte Suppli
Publicado: (2014)

Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance
por: Kato, Chihiro, et al.
Publicado: (2021)

Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England
por: Requena, Gema, et al.
Publicado: (2023)

Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials
por: Han, Jiangna, et al.
Publicado: (2013)

Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease
por: Inui, Naoki, et al.
Publicado: (2015)

Real-world Safety and Efficacy of Indacaterol Maleate in Patients with Chronic Obstructive Pulmonary Disease: Evidence from the Long-term Post-marketing Surveillance in Japan
por: Taniguchi, Tomoko, et al.
Publicado: (2021)

Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort
por: Singh, Mukesh P
Publicado: (2013)

Effect of Indacaterol on Cough and Phlegm in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Five Randomized Controlled Trials
por: Park, Jinkyeong, et al.
Publicado: (2015)

Indacaterol: a comprehensive review
por: Rossi, Andrea, et al.
Publicado: (2013)

Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial
por: Kalberg, Chris, et al.
Publicado: (2016)

Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences
por: Ohno, Takeshi, et al.
Publicado: (2014)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium
por: Pelaia, Girolamo, et al.
Publicado: (2014)

Chronic Obstructive Pulmonary Disease: Is Social Injustice the Elephant in the Room?
por: Chapman, Kenneth R.
Publicado: (2021)

Systematic review comparing LABA, olodaterol, and indacaterol: limitations
por: Donohue, James F
Publicado: (2014)

Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study
por: Hsieh, Meng-Jer, et al.
Publicado: (2022)

Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease - a randomized, multicenter, double-blind, placebo-controlled study
por: Watz, Henrik, et al.
Publicado: (2014)

Pneumonia in Patients with Chronic Obstructive Pulmonary Disease
por: Restrepo, Marcos I., et al.
Publicado: (2018)

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study
por: Salomon, Joerg, et al.
Publicado: (2017)

Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma
por: Chapman, Kenneth R., et al.
Publicado: (2021)

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study
por: Dahl, Ronald, et al.
Publicado: (2013)

Pathogenesis of hyperinflation in chronic obstructive pulmonary disease
por: Gagnon, Philippe, et al.
Publicado: (2014)

Predictors of Readmission, for Patients with Chronic Obstructive Pulmonary Disease (COPD) – A Systematic Review
por: Chow, Ronald, et al.
Publicado: (2023)

Safety of indacaterol in the treatment of patients with COPD
por: Donohue, James F, et al.
Publicado: (2011)

An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease
por: Cazzola, Mario, et al.
Publicado: (2021)

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]
Publicado: (2014)

Comparative effects of capsaicin in chronic obstructive pulmonary disease and asthma (Review)
por: Dumitrache, Mihai-Daniel, et al.
Publicado: (2021)

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol
por: Beier, Jutta, et al.
Publicado: (2011)

Pulmonary embolism with chronic obstructive pulmonary disease
por: Yang, Ruohan, et al.
Publicado: (2021)

If All That You Have Is a Hammer…: Can We Phenotype Our Patients with Chronic Obstructive Pulmonary Disease?
por: Chapman, Kenneth R.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n4vc9v98vssberp5bgjpvmtkc0